Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 5, 2009, Pages 997-1002

  Senti, Gabriela ^a   Graf, Nicole ^a   Haug, Susanne ^a   Rüedi, Nadine ^a   von Moos, Seraina ^a   Sonderegger, Theodor ^a   Johansen, Pål ^a   Kündig, Thomas M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Allergen specific immunotherapy; grass pollen allergy; patch; randomized clinical trial; rhinoconjunctivitis

Indexed keywords

BETAMETHASONE DIPROPIONATE; BUDESONIDE PLUS FORMOTEROL; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CROMOSOL OPHTA; DESLORATADINE; DIPROLEN; FEXOFENADINE; GRASS POLLEN EXTRACT; KETOTIFEN FUMARATE; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; PHLEUM PRATENSE EXTRACT; PLACEBO; SALBUTAMOL; SPERSALLERG; SPERSAPOLYMYXIN; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; APPLICATION SITE SWELLING; ARTICLE; ASTHMA; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; FOLLOW UP; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOTHERAPY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEUM PRATENSE; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCAR; SKIN TEST; SKIN TINGLING; T LYMPHOCYTE; TREATMENT OUTCOME; URTICARIA; VERTIGO;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ECZEMA; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; NASAL PROVOCATION TESTS; PHLEUM; PLACEBOS; POLLEN; SKIN TESTS; YOUNG ADULT;

EID: 71749106471     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.07.019     Document Type: Article

References (35)

1. Arbes Jr. S.J., Gergen P.J., Elliott L., and Zeldin D.C. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 116 (2005) 377-383
2. Stewart II G.E., and Lockey R.F. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 90 (1992) 567-578
3. Dolz I., Martinez-Cocera C., Bartolome J.M., and Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 51 (1996) 489-500
4. Varney V.A., Hamid Q.A., Gaga M., Ying S., Jacobson M., Frew A.J., et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92 (1993) 644-651
5. Pierson-Mullany L.K., Jackola D., Blumenthal M., and Rosenberg A. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 84 (2000) 241-243
6. Larche M., Akdis C.A., and Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 (2006) 761-771
7. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999) 468-475
8. Anonymous. Epidemiology surveys and Danske equities. Hørsholm, Denmark: ALK-Abelló; (2005)
9. Frew A.J. Sublingual immunotherapy. N Engl J Med 358 (2008) 2259-2264
10. Penagos M., Passalacqua G., Compalati E., Baena-Cagnani C.E., Orozco S., Pedroza A., et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 133 (2008) 599-609
11. Roder E., Berger M.Y., de Groot H., and van Wijk R.G. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 19 (2008) 197-207
12. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371 (2008) 2019-2025
13. Glenn G.M., Taylor D.N., Li X., Frankel S., Monemarano A., and Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6 (2000) 1403-1406
14. Turjanmaa K., Darsow U., Niggemann B., Rance F., Vanto T., and Werfel T. EAACI/GA2LEN position paper: present status of the atopy patch test. Allergy 61 (2006) 1377-1384
15. Senti G., Prinz Vavricka B.M., Graf N., Johansen P., Wüthrich B., and Kündig T.M. Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 98 (2007) 134-138
16. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., and Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci U S A 97 (2000) 371-376
17. Takigawa M., Tokura Y., Hashizume H., Yagi H., and Seo N. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Ann N Y Acad Sci 941 (2001) 139-146
18. Bins A.D., Jorritsma A., Wolkers M.C., Hung C.F., Wu T.C., Schumacher T.N., et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11 (2005) 899-904
19. Klimuk S.K., Najar H.M., Semple S.C., Aslanian S., and Dutz J.P. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J Invest Dermatol 122 (2004) 1042-1049
20. Zhao Y.L., Murthy S.N., Manjili M.H., Guan L.J., Sen A., and Hui S.W. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 24 (2006) 1282-1290
21. Kenney R.T., Yu J., Guebre-Xabier M., Frech S.A., Lambert A., Heller B.A., et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 190 (2004) 774-782
22. Partidos C.D., Beignon A.S., Semetey V., Briand J.P., and Muller S. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine 19 (2001) 2708-2715
23. Bergstresser P.R., Fletcher C.R., and Streilein J.W. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dermatol 74 (1980) 77-80
24. Celluzzi C.M., and Falo Jr. L.D. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 108 (1997) 716-720
25. Romani N., Koide S., Crowley M., Witmer-Pack M., Livingstone A.M., Fathman C.G., et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169 (1989) 1169-1178
26. Blamoutier P., Blamoutier J., and Guibert L. [Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling.]. Presse Med 67 (1959) 2299-2301
27. Eichenberger H., and Storck H. Co-seasonal desensitization of pollinosis with the scarification method of Blamoutier. Acta Allergologica XXI (1965) 261-267
28. Wang B., Feliciani C., Howell B.G., Freed I., Cai Q., Watanabe H., et al. Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol 168 (2002) 3303-3308
29. Hauser C., Saurat J.H., Schmitt A., Jaunin F., and Dayer J.M. Interleukin 1 is present in normal human epidermis. J Immunol 136 (1986) 3317-3323
30. Camp R., Fincham N., Ross J., Bird C., and Gearing A. Potent inflammatory properties in human skin of interleukin-1 alpha-like material isolated from normal skin. J Invest Dermatol 94 (1990) 735-741
31. Corsini E., and Galli C.L. Epidermal cytokines in experimental contact dermatitis. Toxicology 142 (2000) 203-211
32. Inoue J., Yotsumoto S., Sakamoto T., Tsuchiya S., and Aramaki Y. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice. J Control Release 108 (2005) 294-305
33. Strid J., Hourihane J., Kimber I., Callard R., and Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 34 (2004) 2100-2109
34. Inoue J., and Aramaki Y. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides. Vaccine 25 (2007) 1007-1013
35. Cumberbatch M., Dearman R.J., Antonopoulos C., Groves R.W., and Kimber I. Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-alpha- and IL-1beta-dependent mechanism. Immunology 102 (2001) 323-330